Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

被引:27
|
作者
Lipton, RB
Pascual, J
Goadsby, PJ
Massiou, H
McCarroll, KA
Vandormael, K
Jiang, KH
Lines, CR
机构
[1] Innovat Med Res Inc, Stamford, CT 06905 USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Univ Hosp Marques de Valdecilla, Santander, Spain
[4] Neurol Inst, London, England
[5] Hop Lariboisiere, F-75475 Paris, France
[6] Merck Res Labs, West Point, PA USA
来源
HEADACHE | 2001年 / 41卷 / 08期
关键词
rizatriptan; sumatriptan; naratriptan; zolmitriptan; 5-HT1B/1D receptor agonists; migraine; nausea; baseline; emergent;
D O I
10.1046/j.1526-4610.2001.01139.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack. Methods.-Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were retrospectively analyzed. Migraine was diagnosed according to International Headache Society criteria. Presence or absence of nausea was recorded at baseline and at 0.5, 1, 1.5, and 2 hours after dosing. The end points analyzed were relief of nausea in those who had it at baseline and emergence of nausea in those who were free of it at baseline. Treatments were compared using odds ratios estimated from logistic regression models at 2 hours, and averaged odds ratios for the first 2 hours posttreatment. Results.-Approximately 60% of patients in each treatment group had nausea at baseline. In those patients with nausea at baseline, significantly more patients treated with rizatriptan 10 mg were free of nausea at 2 hours compared with sumatriptan 100 mg (66% versus 58%, P=.043), sumatriptan 50 mg (68% versus 57%, P=.010), sumatriptan 25 mg (68% versus 59%, P=.017), and naratriptan 2.5 mg (59% versus 45%, P=.014). Averaging over the four posttreatment time points in the first 2 hours, significantly more patients treated with rizatriptan 10 mg were free of nausea compared with sumatriptan 100 mg (P=.004), sumatriptan 50 mg (P=.001), and naratriptan 2.5 mg (P=.015). No significant differences in nausea relief were seen between rizatriptan 10 mg and zolmitriptan 2.5 mg, either at 2 hours (65% versus 61%, P=.210) or over the first 2 hours (P=.781). Rates of treatment-emergent nausea at 2 hours ranged from 11% to 18% with placebo, from 5% to 13% with rizatriptan 10 mg, and from 10% to 20% with other comparator triptans. Conclusions.-Oral rizatriptan 10 mg was more effective than oral sumatriptan and naratriptan at eliminating nausea within 2 hours in patients who had it at baseline. Rates of emergent nausea in patients who were free of it at baseline were low, and no consistent differences were observed between active treatments.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 50 条
  • [1] Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
    John H. Krege
    Richard B. Lipton
    Simin K. Baygani
    Mika Komori
    Sinéad M. Ryan
    Maurice Vincent
    Pain and Therapy, 2022, 11 : 701 - 712
  • [2] Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
    Krege, John H.
    Lipton, Richard B.
    Baygani, Simin K.
    Komori, Mika
    Ryan, Sinead M.
    Vincent, Maurice
    PAIN AND THERAPY, 2022, 11 (02) : 701 - 712
  • [3] Restoring migraine sufferers' ability to function normally: A comparison of rizatriptan and other triptans in randomized trials
    Bussone, G
    D'Amico, D
    McCarroll, KA
    Gerth, W
    Lines, CR
    EUROPEAN NEUROLOGY, 2002, 48 (03) : 172 - 177
  • [4] Effect of galcanezumab on migraine headache days in women with menstrual migraine: A post hoc analysis
    MacGregor, E.
    Okonkwo, R.
    Fernandes, M. F.
    Rettiganti, M.
    Detke, H.
    Pavlovic, J. M.
    HEADACHE, 2021, 61 : 87 - 88
  • [5] Variability in Reported Most Bothersome Symptom in Subjects with Acute Migraine with or Without Aura: a Post Hoc Analysis
    Munjal, S.
    Bennett, A.
    HEADACHE, 2017, 57 : 207 - 208
  • [6] Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
    Blumenfeld, Andrew M.
    Goadsby, Peter J.
    Dodick, David W.
    Hutchinson, Susan
    Liu, Chengcheng
    Finnegan, Michelle
    Trugman, Joel M.
    Szegedi, Armin
    HEADACHE, 2021, 61 (03): : 422 - 429
  • [7] Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis
    Ho, Tony W.
    Rodgers, Anthony
    Bigal, Marcelo E.
    HEADACHE, 2009, 49 (03): : 395 - 403
  • [8] Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
    Wang, Shuu-Jiun
    Kim, Byung-Kun
    Wang, Hebo
    Zhou, Jiying
    Wan, Qi
    Yu, Tingmin
    Lian, Yajun
    Arkuszewski, Michal
    Ecochard, Laurent
    Snellman, Josefin
    Wen, Shihua
    Yin, Fangfang
    Li, Zheng
    Su, Wendy
    Yu, Shengyuan
    HEADACHE, 2024,
  • [9] Intravenous fluids for migraine: a post hoc analysis of clinical trial data
    Balbin, Jerome Edward B.
    Nerenberg, Rebecca
    Baratloo, Alireza
    Friedman, Benjamin W.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (04): : 713 - 716
  • [10] Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial
    Dodick, David W.
    Tepper, Stewart J.
    Friedman, Deborah I.
    Gelfand, Amy A.
    Kellerman, Donald J.
    Schmidt, Peter C.
    HEADACHE, 2018, 58 (07): : 986 - 992